Medicine for prevention of and treatment for amyloidosis
AssigneeNipro Corporation
InventorsHirofumi Kai, Yukio Ando
Life of this patent
Estimating the term…
Abstract
A pharmaceutical for the prophylaxis and/or treatment of amyloidosis such as familial amyloid polyneuropathy is provided. A pharmaceutical for the prophylaxis and/or treatment of amyloidosis that contains a compound containing the trivalent chromium ion, such as a fatty acid chromium salt, as an active ingredient, and that is capable of suppressing the decomposition of mutant transthyretin in amyloidosis.
Claims20
A pharmaceutical for the prophylaxis and/or treatment of amyloidosis, which comprises a compound comprising a trivalent chromium ion as an active ingredient.
A pharmaceutical to suppress decomposition of a mutant transthyretin in amyloidosis, which comprises a compound comprising a trivalent chromium ion as an active ingredient.
A method of preventing or treating amyloidosis in a mammal, which method comprises administering a pharmaceutical composition to a mammal in which amyloidosis needs to be prevented or treated, wherein the pharmaceutical composition comprises a compound comprising a trivalent chromium ion as an active ingredient.
A method of suppressing decomposition of a mutant transthyretin in amyloidosis in a mammal, which method comprises administering a pharmaceutical composition to a mammal in which there is decomposition of a mutant transthyretin in amyloidosis, wherein the pharmaceutical composition comprises a compound comprising a trivalent chromium ion as an active ingredient.
Dependencies are inferred from the claim text.